Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 18/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22215286 | 1.00 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL8434628 | 1.00 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL4841218 | 0.98 | SLC6A2 (0.37) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL12362618 | 0.87 | NOS2 (0.38) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| SCHEMBL24242503 | 0.87 | NOS2 (0.38) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| SCHEMBL5646119 | 0.86 | SLC6A2 (0.36) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL20362240 | 0.85 | NOS2 (0.37) | SLC6A4SLC6A2NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL28747733 | 0.84 | SLC6A2 (0.35) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL13503192 | 0.80 | — | — | |
| SCHEMBL13503178 | 0.78 | NOS3 (0.35) | SLC6A4SLC6A2SLC6A3NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| WO-2021215544-A1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | WO | disclosed |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | KRAS, NRAS, HRAS | SLC6A4 4720/4885SLC6A2 4755/4885SLC6A3 4622/4885 |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | MCHR1, MCHR2, MC1R | SLC6A4 554/4885SLC6A2 343/4885SLC6A3 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.